Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.47 |
| ▸ | AURKA | O14965 | 11/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.47 |
| ▸ | PLK1 | P53350 | 3/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL9941222 | 0.96 | CDK2 (0.47) | CDK2PDPK1CCNA2AURKACCNA1 | |
| SCHEMBL9941223 | 0.90 | CDK2 (0.45) | CDK2PDPK1CCNA2AURKACCNA1 | |
| SCHEMBL9941217 | 0.82 | CDK2 (0.48) | CDK2CCNA2AURKACCNA1PLK1 | |
| SCHEMBL15377272 | 0.79 | CDK2 (0.49) | CDK2CCNA2AURKACCNA1PLK1 | |
| SCHEMBL11024059 | 0.78 | MAPKAPK2 (0.47) | CDK2CCNA2AURKACCNA1MAPKAPK2 | |
| Hydrochloric Acid SCHEMBL6793621 | 0.77 | MAPKAPK2 (0.43) | CDK2PDPK1CCNA2AURKACCNA1 | |
| SCHEMBL9940634 | 0.76 | CDK2 (0.63) | CDK2PDPK1CCNA2AURKACCNA1 | |
| SCHEMBL18751649 | 0.74 | CDK2 (0.50) | CDK2CCNA2AURKACCNA1PLK1 | |
| Trifluoroacetic Acid SCHEMBL9940945 | 0.73 | CDK2 (0.53) | CDK2PDPK1CCNA2AURKACCNA1 | |
| SCHEMBL12698369 | 0.73 | CDK2 (0.60) | CDK2CCNA2AURKACCNA1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614065-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-07-17 | — | — | EP | claimed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | claimed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | claimed |
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | CDK2 113/4885PDPK1 22/4885CCNA2 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.